MedTrace Logo

Detecting Colorectal Cancer With Liver Metastatic Lesions Using Novel Precise Imaging Tools

NCT06935149 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-04-24

No results posted yet for this study

Summary

This study will demonstrate the diagnostic utility of PSMA PET among patients with CRC with liver metastasis.

Conditions

  • Liver Metastasis Colon Cancer

Interventions

DRUG

18-PSMA

Intravenous push 4 MBq/kg per patient (for a 70 kg patient, 280 MBq of \[18F\]FPSMA needs to be intravenously injected), and the maximum dose cannot exceed 400 MBq. After the injection of \[18F\]FPSMA, intravenous flushing was performed with 20 ml of normal saline.

Sponsors & Collaborators

  • Kaohsiung Chang Gung Memorial Hospital,Taiwan

    collaborator UNKNOWN

  • Primo Biotechnology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2025-12-31
Completion
2025-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06935149 on ClinicalTrials.gov